R2 Hemostasis Diagnostics India Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 7.94 M
as on 16-11-2024
- Company Age 14 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -41.33%
(FY 2023)
- Profit -98.03%
(FY 2023)
- Ebitda -94.07%
(FY 2023)
- Net Worth 0.58%
(FY 2023)
- Total Assets 11.94%
(FY 2023)
About R2 Hemostasis Diagnostics India
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 7.94 M, as per Ministry of Corporate Affairs (MCA) records.
Michael Morris, Sumit Agarwal, and Daniel Smogor serve as directors at the Company.
- CIN/LLPIN
U74992UP2010FTC041987
- Company No.
041987
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
15 Sep 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does R2 Hemostasis Diagnostics India Private Limited offer?
R2 Hemostasis Diagnostics India Private Limited offers a wide range of products and services, including Rapid Test Kit, Diagnostic Test Kit, Cardiac Drugs, Anticoagulant and Antiplatelet Drugs.
Who are the key members and board of directors at R2 Hemostasis Diagnostics India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumit Agarwal  | Director | 24-Dec-2014 | Current |
Michael Morris  | Director | 15-Sep-2010 | Current |
| Daniel Smogor | Director | 15-Sep-2010 | Current |
Financial Performance of R2 Hemostasis Diagnostics India.
R2 Hemostasis Diagnostics India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 41.33% decrease. The company also saw a substantial fall in profitability, with a 98.03% decrease in profit. The company's net worth moved up by a moderate rise of 0.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of R2 Hemostasis Diagnostics India?
In 2023, R2 Hemostasis Diagnostics India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Scorgemi Scientific Solutions Private LimitedActive 1 year 3 monthsSumit Agarwal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at R2 Hemostasis Diagnostics India?
Unlock and access historical data on people associated with R2 Hemostasis Diagnostics India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of R2 Hemostasis Diagnostics India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped R2 Hemostasis Diagnostics India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
